Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L35a pseudogene 2 (RPL35AP2) is a processed pseudogene with sequence similarity to the functional ribosomal protein L35a gene but does not encode a functional protein and is not known to be transcribed or translated[1][6]. Pseudogenes like RPL35AP2 arise from gene duplication or retrotransposition events and typically do not produce active protein products. RPL35AP2 is not considered a therapeutic target; it lacks catalytic, signaling, or receptor activity and does not belong to conventional therapeutic target classes such as enzymes or receptors[1][6][4]. While some pseudogenes have been reported to play regulatory roles in gene expression, there are no published data specifically linking RPL35AP2 to such functions, to disease biology, or to interaction with approved drugs[1][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L35a pseudogene 2 (RPL35AP2).